

Insulin and GLP-1 RA combination agents

Applies To:

lixisenatide 33 mcg /100 U insulin glargine (SOLIQUA)
 liraglutide 3.6 mg/100 U insulin degludec (XULTOPHY)

Diagnoses Considered for Coverage:

- Management of Diabetes Mellitus Type 2 (DM-2)

Coverage Criteria:

For diagnosis of type 2 diabetes mellitus:

- Not being used in combination with another GLP-1 RA agent (e.g. Adlyxin, Bydureon, Byetta, Ozempic, Soliqua, Rybelsus, Trulicity, Victoza, Xultophy, Mounjaro, Wegovy, Saxenda), **and**
- Patient is currently receiving BOTH a long-acting (basal) insulin (e.g., Lantus, Lantus Solostar, Toujeo, Levemir, or Tresiba) along with a glucagon-like peptide agent **AND** patient requests to reduce the number of required daily injections, **and**
- Dose does not exceed FDA label maximum.

Coverage Duration: one year

References:

1. Soliqua [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC. 2019.
2. Xultophy [package insert]. Plainsboro, NJ: Novo Nordisk Inc. 2019

Effective Date: 5/3/2023